5th IBDH Annual Symposium - Seattle 2020

5th IBDH Annual Symposium - Seattle 2020 is organized by IBDHorizons and will be held on Mar 07, 2020 at Grand Hyatt Seattle, Seattle, Washington, United States of America.

The target audience is comprised of healthcare providers caring for IBD patients: adult and pediatric gastroenterologists, advanced registered nurse practitioners and physician assistants, medical staff, dietician, surgeons, and pharmacists. This CME Conference has been approved for a maximum of 6 AMA PRA Category 1 Credits™.

Description:
5th IBDH Annual Symposium - Seattle 2020. Meeting offers you:
• Relevant and engaging presentations by renowned speakers
• A forum to collaborate with others and ask questions and share your experiences
• A place to reflect upon and refine your practices

Statement of Need/Program Overview:
• This activity is jointly provided by UI School of Medicine and IBD Horizons.
• The management of IBD is highly dynamic with extensive, cutting-edge information deriving from a wealth of ongoing scientific, clinical, and therapeutic research programs. The mission of IBD Horizons® is to provide healthcare providers with the opportunity to enhance their clinical knowledge by providing the most up-to-date information regarding the management of IBD. Cutting edge topics delivered by respected educators/leaders in the IBD field, as well as opportunities for interaction between the presenters and participants, have been designed into the educational program.

Learning Objectives:
•  Review the common extraintestinal manifestations in IBD apply practical approach to screen and intervene as needed
•  Appraise the currently available evidence of the effect of Cannabis and supplements in IBD 
•  Discuss the newly approved and soon to be approved biologic and non-biologic therapies for IBD, including the risks, efficacy and special considerations when utilizing these therapies  
•  Describe and understand the comparative efficacy of the currently available therapies and the rationale for optimal positioning of these options in IBD today
•  Incorporate the concept of treat to target in IBD clinical practice and evaluate effectively how to incorporate into IBD management and goals of care
•  Examine the current management of fibrostenotic Crohn’s complications and apply best up-to-date medical and surgical treatment strategies
•  Apply up-to-date practice in managing dysplasia in IBD from detection to endoscopic and surgical intervention
Identify the most promising therapies including antibodies and small molecules in late-stage clinical development, with an emphasis on immunological targets and pharmacological properties

Additional details will be posted as soon as they are available.